Presentation is loading. Please wait.

Presentation is loading. Please wait.

Immune Ageing and Viral Co-Factors

Published byLucy Summers Modified over 7 years ago

Similar presentations

Presentation on theme: "Immune Ageing and Viral Co-Factors"— Presentation transcript:

1 Immune Ageing and Viral Co-Factors
Peter W. Hunt, MD Associate Professor of Medicine Division of Experimental Medicine, UCSF

2 Disclosures Consultant Merck Gilead Viiv

3 Potential Role of Inflammation in Driving Morbidity in Older HIV+ Individuals
ART Toxicity Age- associated Morbidity Lifestyle Persistent Inflammation CMV HCV Deeks and Phillips, BMJ, 2009

4 CMV

5 10% of circulating memory T cell repertoire is CMV-specific!
CMV elicits massive immune responses even in asymptomatic HIV- individuals 10% of circulating memory T cell repertoire is CMV-specific! Sylwester/Picker, JEM, 2005

6 CD8+ T Cell Proliferation & Maturation with CMV
↑Telomere Length CD57+, ↓Telomere Length “Senescence” phenotype associated with mortality in elderly Wikby, Exp Ger, 2002 Hadrup, JI, 2006 Antigen Lee, PLoS One, 2014 CD28- Memory CD8+ Cells CD28+CD27+ CCR7+RA- CD27+CCR7-RA- CD27-CCR7-RA- CD27-CCR7-RA+ Central Memory Transitional Effector Memory TEMRA

7 CMV does not impair (and may enhance) flu vaccine responses in young HIV- individuals
Old CMV IgG- CMV IgG+ Furman/Davis, Science Transl Med, 2015

8 CMV Causes CD8 Expansion and Inflammation in HIV Infection
CD8+ T Cell Counts IP-10 sTNF-RII D-Dimer CMV causes ↑CX3CR1 expression, trafficking of T cells/monos to vascular tissue CX3CR1+ CD8s also express PAR-1, which can activate coagulation cascade CMV viremia (or prior end organ dz) predicts venous thromboembolism in HIV Freeman, JID, 2014 (see also: Sacre, AIDS, 2011; Mudd, JID, 2016; Musselwhite, AIDS 2011)

9 in HIV+ Patients with CD4<350 despite ART
Blocking Asymptomatic CMV Replication with Valganciclovir ↓ Immune Activation in HIV+ Patients with CD4<350 despite ART -4.4% HIV- Median Valacyclovir, which has strong anti-HSV1/2 but minimal anti-CMV activity, failed to decrease immune activation (Yi et al, CID, 2013). Hunt et al, JID, 2011

10 Cardiovascular Effects of CMV

11 Higher CMV-specific CD8 IFN-g Production Associated with More Atherosclerosis
Hsue et al, AIDS, 2006 (see also: Parrinello, JID, 2012; Lo, AIDS, 2010)

12 CMV Sero-status Predicts Non-AIDS Events
(and less so AIDS…): ICONA Cohort Strongest effect for CAD (HR 2.3) CMV replicates in vascular endothelium and appears to contribute to transplant vasculopathy (Valantine, Circ, 1999) Lichtner et al, JID, 2015 (see also Hsue, AIDS, 2006)

13 A role of CMV in other aspects of HIV pathogenesis?

14 CMV may plausibly drive clonal proliferation of HIV-infected cells
Seminal CMV Shedding Associated with Higher PBMC HIV Reservoirs during ART CMV may plausibly drive clonal proliferation of HIV-infected cells Gianella, JV, 2014

15 CMV May Also Contribute to Microbial Translocation in HIV Infection
Maidji, PLoS Path, 2017

16 Hepatitis C Virus

17 No increased risk of CAD or cancer
HCV appeared to increase the risk of: T2DM Kidney disease Osteoporotic fractures Only T2DM risk declined with Rx (IFN-based) (see also editorial by Lo Re III, CID, 2017)

18 Comparable reductions in sCD163 (P≤0.0004 for both)
Greater and More Rapid Reversal of Type I IFN Signaling with DAA vs IFN-based HCV Rx IFN-based SVR Baseline Week 4 Week 12 P=0.004 -19% -47% DAA-based SVR Baseline Week 4 Week 12 P<0.001 -73% -70% Comparable reductions in sCD163 (P≤ for both) Good: DAAs reduce biomarkers that predict morbidity Bad: DAAs may result in loss of HBV control Mascia, PLoS One, 2017 (also: Tenorio, JID, 2014; Knudsen, JID, 2016; Chen, Hepatology, 2017)

19 Early Increase in LDL Cholesterol during DAA Treatment of HCV
Oxidized LDL also increases during DAA Tx (Biliotti, CROI 2017, #575) Restoration of health or increased CAD risk? IFNs may suppress LDL (Schectman, Arterio Thromb 1992) Townsend, ARHR, 2016 (see also Frias, CROI 2017, #573)

20 Reactive Hyperemia Index
Inconsistent Effects of DAA-based HCV Tx on CAD Surrogate Markers in Treated HIV (n=20) Reactive Hyperemia Index by peripheral arterial tonometry D-dimer Level (ng/ml) Baseline Post-SVR Better Worse Baseline Post-SVR …but sICAM-1, sE-selectin, and sCD163 all declined (P<0.01) Chew, Int. Co-Morbidities Workshop, 2016

21 Summary CMV appears to increase immune activation in treated HIV and may plausibly contribute to: Cardiovascular, thromboembolic disease HIV reservoirs and microbial translocation Need an interventional study to assess these hypotheses HCV treatment with DAAs causes massive reversal of Type I interferons Impact on CAD surrogate markers is mixed Impact on extra-hepatic events still unclear

22 Acknowledgements Hunt and McCune Labs Core Immunology Lab UCSD
Elizabeth Sinclair, Lorrie Epling Jeff Milush, Chris Baker SFGH Cardiology Priscilla Hsue UARTO Helen Byakwaga David Bangsberg Mark Siedner NIAID/VRC Jason Brenchley Danny Douek University of Sao Paulo Vivian Avelino-Silva Esper Kallas CWRU Michael Lederman Mike Freeman Hunt and McCune Labs Rachel Rutishauser Josh Vasquez Charline Bacchus-Souffan Louise Swainson Ma Somsouk Sulggi Lee Ivan Vujkovich-Cvijin Mike McCune SCOPE/OPTIONS/UCSF Steve Deeks Jeff Martin Hiroyu Hatano Rick Hecht Chris Pilcher Rebecca Hoh SCOPE and OPTIONS Teams UCSF Drug Studies Unit Yong Huang UCSD Sara Gianella Davey Smith UCLA Kara Chew R01AI110271, R56AI100765, 1R21AI087035, 1R21AI07877 DDCF CSDA Roche, Inc.

Download ppt "Immune Ageing and Viral Co-Factors"

Similar presentations

Hepatitis B & Hepatitis C in HIV

Hepatitis B & Hepatitis C in HIV
Impact of Tryptophan Catabolism on CD4+ T Cell Recovery and Mortality in HIV-infected Ugandans Initiating ART Peter W. Hunt, Sheri Weiser, Yong Huang,

Impact of Tryptophan Catabolism on CD4+ T Cell Recovery and Mortality in HIV-infected Ugandans Initiating ART Peter W. Hunt, Sheri Weiser, Yong Huang,
Immune-Based Interventions for HIV Infection and AIDS Alan Landay, PhD Professor and Chairman Department of Immunology/Microbiology Rush University Medical.

Immune-Based Interventions for HIV Infection and AIDS Alan Landay, PhD Professor and Chairman Department of Immunology/Microbiology Rush University Medical.
Evaluation of Human Thymic Function during Health and HIV-1 Infection

Evaluation of Human Thymic Function during Health and HIV-1 Infection
Www.aids2014.org HCV cure: new treatment paradigms for HCV infection Sanjay Bhagani Consultant Physician/Senior Lecturer Royal Free Hospital/UCL London.

HCV cure: new treatment paradigms for HCV infection Sanjay Bhagani Consultant Physician/Senior Lecturer Royal Free Hospital/UCL London.
Washington D.C., USA, 22-27 July 2012www.aids2012.org Access to HCV treatment for people with HIV/HCV Professor Gregory Dore Viral Hepatitis Clinical Research.

Washington D.C., USA, July 2012www.aids2012.org Access to HCV treatment for people with HIV/HCV Professor Gregory Dore Viral Hepatitis Clinical Research.
BORDERNETwork Training on HIV and HBV Co-Infections Dr. med. Wolfgang Güthoff / Alexander Leffers, M.A. www.bordernet.eu www.aidshilfe-potsdam.de.

BORDERNETwork Training on HIV and HBV Co-Infections Dr. med. Wolfgang Güthoff / Alexander Leffers, M.A.
Www.aids2014.org Comparison between Pathogenic and Nonpathogenic SIV Infections and Focus on Mucosal Tissue Compartment Reveal a Critical Role for the.

Comparison between Pathogenic and Nonpathogenic SIV Infections and Focus on Mucosal Tissue Compartment Reveal a Critical Role for the.
Www.ias2011.org Immuno-virological discordance in treated suppressed patients Julià Blanco IGTP/IrsiCaixa Badalona, Catalonia, Spain.

Immuno-virological discordance in treated suppressed patients Julià Blanco IGTP/IrsiCaixa Badalona, Catalonia, Spain.
HLA-B57 does not fully explain the ability of HIV controllers to clear HCV infection Alice K. Asher 1, RN, MS; Glenn-Milo Santos 1, MPH; Jennifer Evans,

HLA-B57 does not fully explain the ability of HIV controllers to clear HCV infection Alice K. Asher 1, RN, MS; Glenn-Milo Santos 1, MPH; Jennifer Evans,
Should we treat HIV Controllers ? IAS 2013 Pr Olivier Lambotte Department of internal medicine and clinical immunology Bicêtre Hospital, University Paris.

Should we treat HIV Controllers ? IAS 2013 Pr Olivier Lambotte Department of internal medicine and clinical immunology Bicêtre Hospital, University Paris.
The role of HIV infection and Co-infections in Serious Non-AIDS Events Peter W. Hunt, M.D Associate Professor of Medicine, UCSF.

The role of HIV infection and Co-infections in Serious Non-AIDS Events Peter W. Hunt, M.D Associate Professor of Medicine, UCSF.
The pathogenesis of persistent HIV-associated inflammation during long-term antiretroviral therapy Steven G. Deeks Professor of Medicine University of.

The pathogenesis of persistent HIV-associated inflammation during long-term antiretroviral therapy Steven G. Deeks Professor of Medicine University of.
Slide 1 of 11 From CB Hicks, MD, at Chicago, IL: May 20, 2013, IAS-USA. IAS–USA Charles B. Hicks, MD Professor of Medicine Duke University Medical Center.

Slide 1 of 11 From CB Hicks, MD, at Chicago, IL: May 20, 2013, IAS-USA. IAS–USA Charles B. Hicks, MD Professor of Medicine Duke University Medical Center.
Immunosenescence - Results of BELFRAIL (and INCIVAR) By Adriaensen Wim Department of Public Health and Primary Care, KU Leuven & UCL, Belgium.

Immunosenescence - Results of BELFRAIL (and INCIVAR) By Adriaensen Wim Department of Public Health and Primary Care, KU Leuven & UCL, Belgium.
Why is inflammation elevated in treated HIV infection and why does it matter? Steven G. Deeks Professor of Medicine University of California, San Francisco.

Why is inflammation elevated in treated HIV infection and why does it matter? Steven G. Deeks Professor of Medicine University of California, San Francisco.
Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,

Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,
2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.

2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.
Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity Peter W. Hunt, MD Associate Professor of Medicine UCSF HIV/AIDS Division.

Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity Peter W. Hunt, MD Associate Professor of Medicine UCSF HIV/AIDS Division.
Long Term Management of HIV Infection in Aging Adults: Current Challenges, Future Strategies Andrew Zolopa, MD Stanford University.

Long Term Management of HIV Infection in Aging Adults: Current Challenges, Future Strategies Andrew Zolopa, MD Stanford University.

Similar presentations

Ads by Google